Replies to post #5293 on Dendreon Corp fka DNDNQ

[rancherho]

Good point, although when CEGE began Vital-1 enrollment in July 2004, they probably did not have a breakdown for the median survival of 22 to 23 months for the 45% asymptomatic subgroup in its Taxotere TAX327 pivotal trial in AIPC, nor the median survival for the 32 high dose GVAX patients in its two Phase 2 trials, which has since been reported as 34.9 months an 35.0 months respectively. CEGE's CEO took great pains yesterday to point out that the Phase 2 trials were multi-institutional; he claimed that measures were taken to reduce any selection bias; and he pointed out that there were both T cell and B cell based immune responses. All of this is not to suggest that GVAX statistical significance or FDA approval is assured, but I've yet to come across any strong reason why it's likley to fail. JMHO.